Trial Profile
A Phase 2, Multiple Dose, Open-Label, Parallel-Group, Active Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACP-001 in Adult Patients With Growth Hormone Deficiency
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lonapegsomatropin (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Ascendis Pharma
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
- 05 Mar 2015 Results presented at Pediatric Endocrinology - Clinical Translational Session in March 2015, according to an Ascendis Pharma media release.
- 24 Oct 2013 New trial record